Notably, ABPS enhances cisplatin chemosensitivity in breast cancer by disrupting the PD-1/PD-L1 immune checkpoint axis, thereby reversing tumor immunosuppression and improving chemotherapeutic efficacy (Lei et al., 2024). This evidence concerns the gene CD274 and breast carcinoma.